Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria

TY - JOUR

T1 - Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria

AU - Cavanagh, David R

AU - Dodoo, Daniel

AU - Hviid, Lars

AU - Kurtzhals, Jørgen

AU - Theander, Thor G

AU - Akanmori, Bartholomew D

AU - Polley, Spencer

AU - Conway, David J

AU - Koram, Kojo

AU - McBride, Jana S

N1 - Keywords: Amino Acid Sequence; Animals; Antibodies, Protozoan; Child; Ghana; Humans; Incidence; Longitudinal Studies; Malaria, Falciparum; Merozoite Surface Protein 1; Molecular Sequence Data; Plasmodium falciparum; Prospective Studies; Seasons; Survival Analysis

PY - 2004

Y1 - 2004

N2 - This longitudinal prospective study shows that antibodies to the N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical malaria in an area of stable but seasonal malaria transmission of Ghana. Antibodies to the block 2 region of MSP-1 were measured in a cohort of 280 children before the beginning of the major malaria transmission season. The cohort was then actively monitored for malaria, clinically and parasitologically, over a period of 17 months. Evidence is presented for an association between antibody responses to block 2 and a significantly reduced risk of subsequent clinical malaria. Furthermore, statistical survival analysis provides new information on the duration of the effect over time. The results support a conclusion that the block 2 region of MSP-1 is a target of protective immunity against P. falciparum and, thus, a promising new candidate for the development of a malaria vaccine.

AB - This longitudinal prospective study shows that antibodies to the N-terminal block 2 region of the Plasmodium falciparum merozoite surface protein 1 (MSP-1) are associated with protection against clinical malaria in an area of stable but seasonal malaria transmission of Ghana. Antibodies to the block 2 region of MSP-1 were measured in a cohort of 280 children before the beginning of the major malaria transmission season. The cohort was then actively monitored for malaria, clinically and parasitologically, over a period of 17 months. Evidence is presented for an association between antibody responses to block 2 and a significantly reduced risk of subsequent clinical malaria. Furthermore, statistical survival analysis provides new information on the duration of the effect over time. The results support a conclusion that the block 2 region of MSP-1 is a target of protective immunity against P. falciparum and, thus, a promising new candidate for the development of a malaria vaccine.

U2 - 10.1128/IAI.72.11.6492-6502.2004

DO - 10.1128/IAI.72.11.6492-6502.2004

M3 - Journal article

C2 - 15501780

SN - 0019-9567

VL - 72

SP - 6492

EP - 6502

JO - Infection and Immunity

JF - Infection and Immunity

IS - 11

ER -